Structure-Based Design And Engineering Of A Nontoxic Recombinant Pokeweed Antiviral Protein With Potent Anti-Human Immunodeficiency Virus Activity
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY(2003)
摘要
A molecular model of pokeweed antiviral protein (PAP)-RNA interactions was used to rationally engineer FLP-102 ((151)AA(152)) and FLP-105((191)AA(192)) as nontoxic PAPs with potent anti-human immunodeficiency virus (anti-HIV) activities. FLP-102 and FLP-105 have been produced in Escherichia coli and tested both in vitro and in vivo. These proteins depurinate HIV type 1 (HIV-1) RNA much better than rRNA and are more potent anti-HIV agents than native PAP or recombinant wild-type PAP. They are substantially less toxic than native PAP in BALB/c mice and exhibit potent in vivo activities against genotypically and phenotypically nucleoside reverse transcriptase inhibitor-resistant HIV-1 in a surrogate human peripheral blood lymphocyte (Hu-PBL) SCID mouse model of human AIDS. Rationally engineered nontoxic recombinant PAPs such as FLP-102 and FLP-105 may provide the basis for effective salvage therapies for patients harboring highly drug-resistant strains of HIV-1. The documented in vitro potencies of FLP-102 and FLP-105, their in vivo antiretroviral activities in the HIV-infected Hu-PBL SCID mouse model, and their favorable toxicity profiles in BALB/c mice warrant the further development of these promising new biotherapeutic agents.
更多查看译文
关键词
molecular modeling,plasmids,drug resistance,escherichia coli,protein engineering,wild type,recombinant proteins,purines,drug design
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络